Pressroom

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6-18 Years

Source: Morbidity and Mortality Weekly Report | Vol:Vol. 62 | Page: 521

06/28/2013

In February 2013, the Advisory Committee on Immunization Practices (ACIP) recommended routine the 13-valent pneumococcal conjugate vaccine (PCV13) for prevention of invasive pneumococcal disease in children aged six to 18 years who have immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks, or cochlear implants, and have not previously received PCV13. A study of 158 children, aged six to 18 years, with sickle-cell disease who previously received the 23-valent pneumococcal polysaccharide vaccine (PPSV23) showed that one dose of PCV13 was safe. Recommendations for use of PPSV23 for children in this age group have not changed. The new recommendation changes from permissive and off-label recommendation of PCV13 in the pediatric immunocompromised population to a category A recommendation. PCV13 is already recommended for all children aged two months to 59 months and for children aged 60 to 71 months with chronic medical conditions.



Copyright © 2014 Information, Inc.